Clinical trials: Advanced
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
Ewing's Sarcoma
A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
This study is a randomized, controlled, multicenter, prospective clinical trial with a planned enrollment of 74 patients, who will be randomly assigned in a 2:1 ratio.
- Trial name
- NCT07092306
- Testing
- Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT), Irinotecan Combined with Temozolomide and Vincristine (VIT)
- Volunteers
- 74 people
- Sponsor
- Tang Xiaodong
Muscular Dystrophy, Duchenne
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
- Trial name
- NCT02286947
- Testing
- Eteplirsen
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sarepta Therapeutics, Inc.
Extracranial Germ Cell Tumor, Pediatric
Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor.
The purpose is to evaluate the effectiveness and safety of albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of children patients with advanced, recurrent or refractory extracranial germ cell tumor.
- Trial name
- NCT04581265
- Testing
- albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Pediatric Advanced Life Support (PALS)
Comparing the Effectiveness of Large Language Model-Based and Video-Based Refresher Education on Knowledge Retention After Simulation-Based Pediatric Cardiopulmonary Resuscitation Training: A Six-Month Follow-Up Study
This study aims to compare the effectiveness of large language model (LLM)-based refresher education and video-based refresher education for maintaining knowledge and performance after simulation-based Pediatric Advanced Life…
- Trial name
- NCT07783932
- Testing
- LLM-Based Refresher Education, Video-Based Refresher Education
- Where
- South Korea
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
Advanced Solid Tumor, Metastatic Solid Tumor
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
- Trial name
- NCT06577987
- Testing
- CID-078 Monotherapy
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- Circle Pharma
Non Small Cell Lung Cancer
Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient
The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab. A standard anonymous data collection form will be used to collect data and to analyze it.
- Trial name
- NIVEX (NCT03132493)
- Testing
- Nivolumab 10 MG/ML
- Where
- 61 sites in Spain
- Volunteers
- 676 people
- Sponsor
- Spanish Lung Cancer Group
Effect of Drug, Toxicity, Drug
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse…
- Trial name
- AIEO (NCT04824352)
- Testing
- apatinib
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Peking University People's Hospital
Heart Failure
Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan
The purpose of the study is to evaluate the safety and effectiveness of the HW005 System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.
- Trial name
- HW005 (NCT02091440)
- Testing
- Implant of the HW005 Ventricular Assist System.
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chronic Myeloid Leukemia, Acute Myelogenous Leukemia
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fludarabine as preparative therapy and tacrolimus plus methotrexate as the GVHD…
- Conditions
- Chronic Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia
- Trial name
- NCT00516152
- Testing
- Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Endometrial Cancer
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Primary Objective: To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.
- Trial name
- NCT00388154
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
Ridaforolimus (Deforolimus, AP23573, MK-8669) is an mTor inhibitor shown to have promising activity in adults with a variety of solid malignancies, particularly the sarcomas.
- Trial name
- NCT00704054
- Testing
- ridaforolimus
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Wounds and Injuries
Effects of Advanced Trauma Life Support® on Adult Trauma Patient Outcomes
Rationale: Trauma is a massive global health issue. Many training programmes have been developed to help physicians in the initial management of trauma patients.
- Trial name
- ADVANCE TRAUMA (NCT06321419)
- Testing
- Advanced Trauma Life Support training
- Where
- 10 sites in India
- Volunteers
- 4,320 people
- Sponsor
- Karolinska Institutet
Locally Advanced Non-small Cell Lung Cancer
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
This is a phase II, multicenter, single-arm, non-blind study. To 21 patients with PD-L1 ≥50% locally advanced non-small cell lung cancer, the combination of Pembrolizumab and platinum-doublets will be intravenously administered…
- Trial name
- Evolution (NCT04153734)
- Testing
- Pembrolizumab, Cis Platinum, Carboplatin
- Volunteers
- 21 people
- Sponsor
- Kobe Minimally Invasive Cancer Center
Preterm Birth Complication
Prediction of Adverse Outcome Using Fetal MRI in Pregnancies at Risk of Preterm Birth
1.4% of babies have a very premature birth (PTB) (less than 32 weeks of pregnancy). This can result in severe life-long complications including cerebral palsy, learning and behavioural difficulties and breathing problems.
- Trial name
- NCT05164432
- Testing
- MRI scan
- Where
- United Kingdom
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- King's College London
Leukemia
Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LLC0405 (NCT00462332)
- Testing
- Fludarabine, Campath, Transplant
- Where
- 23 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Non-Small Cell Lung Cancer
Evaluate EGFR Mutation Status and Impact Factors in North China
Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.
- Trial name
- NCT02620657
- Testing
- Non interventional study
- Volunteers
- 2,809 people
- Sponsor
- ying cheng
Advanced Cancer
Doxil, Bevacizumab and Temsirolimus Trial
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer…
- Trial name
- NCT00761644
- Testing
- Doxil, Bevacizumab, Temsirolimus
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center